3-哌啶乙酸 | 74494-52-3

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-哌啶乙酸
• 英文名称: 2-(piperidin-3-yl)acetic acid
• 英文别名: 3-Piperidinylacetic Acid；2-piperidin-1-ium-3-ylacetate
• CAS: 74494-52-3
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: WKXRHAACRPUBIC-UHFFFAOYSA-N

物化性质

• 熔点：
  276-278 °C
• 沸点：
  286.8±13.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)
• 溶解度：
  DCM、甲醇、水

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P304+P340,P302+P352,P305+P351+P338,P301+P312,P261
• 危险性描述：
  H319,H302,H335,H315

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Piperidine acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Piperidine acetic acid
CAS number: 74494-52-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H13NO2
Molecular weight: 143.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-哌啶乙酸 在 吡啶 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 7.5h， 生成 (+)-(R)-1-(Benzyloxycarbonyl)piperidin-3-ethhyl p-Toluolsulfonat
  参考文献：
  名称：

  （+）-（R）-1-Azabicylo [3.3.1] nonan-2-on的合成与最佳免疫

  摘要：

  （+）-（（R）-1-氮杂双环[3.3.1] nonan-2-one的手性意义的合成与测定

  DOI：

  10.1002/hlca.19870700802
• 作为产物：
  描述：

  3-吡啶乙酸 在 二氧化铂 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 16.0h， 以to give 2-(piperidin-3-yl)acetic acid as a slight yellow solid (300 mg, Y: 81%)的产率得到3-哌啶乙酸
  参考文献：
  名称：

  S1P modulating agents

  摘要：

  化合物(I)或(II)的配方可以调节S1P受体的活性。

  公开号：

  US20160263093A1

文献信息

• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS SPHINGOSINE-1-PHOSPHATE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011017578A1

  公开（公告）日：2011-02-10

  Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物，或其立体异构体或药用可接受的盐，其中：A为Formula (II)，Q为取代的5-成员单环杂芳基团；W为CH2、O或NH；而R1、R2、R3、R4、R5、R6、m、n、t和x在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• New thiadiazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2305660A1

  公开（公告）日：2011-04-06

  The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

  本发明涉及式(I)的噻二唑衍生物，它们的制备过程以及包含它们的药物组合物。这些化合物是S1P1受体的强激动剂，因此，它们可用于治疗、预防或抑制那些已知可通过鞘氨醇-1-磷酸受体激动剂（S1P1）改善的疾病和失调，例如自身免疫性疾病、慢性免疫和炎症性疾病、移植排斥反应、恶性肿瘤疾病、与血管生成相关的失调、疼痛、神经系统疾病、病毒和感染性疾病。
• CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
  申请人：FLX Bio, Inc.

  公开号：US20180072743A1

  公开（公告）日：2018-03-15

  Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

  披露的内容包括但不限于，用于调节趋化因子受体活性的化合物及其使用方法。
• Tricyclic compounds useful for inhibition of G-protein function and for
  申请人：Schering Corporation

  公开号：US05672611A1

  公开（公告）日：1997-09-30

  Novel compounds of Formula ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the Formula 1.0 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

  揭示了化学式##STR1##的新化合物。还揭示了一种抑制Ras功能从而抑制细胞异常生长的方法。该方法包括向生物系统施用化合物1.0的步骤。具体来说，该方法抑制了哺乳动物（如人类）中细胞的异常生长。
• Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P₁)
  作者：John L. Gilmore、James E. Sheppeck、Scott H. Watterson、Lauren Haque、Parag Mukhopadhyay、Andrew J. Tebben、Michael A. Galella、Ding Ren Shen、Melissa Yarde、Mary Ellen Cvijic、Virna Borowski、Kathleen Gillooly、Tracy Taylor、Kim W. McIntyre、Bethanne Warrack、Paul C. Levesque、Julia P. Li、Georgia Cornelius、Celia D’Arienzo、Anthony Marino、Praveen Balimane、Luisa Salter-Cid、Joel C. Barrish、William J. Pitts、Percy H. Carter、Jenny Xie、Alaric J. Dyckman

  DOI：10.1021/acs.jmedchem.6b00373

  日期：2016.7.14

  Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. Because of the ability of S1P1 receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases. In this article, the discovery

  鞘氨醇-1-磷酸酯（S1P）是一种具有生物活性的鞘脂代谢产物，可调节多种生理过程，例如淋巴细胞运输，心脏功能，血管发育和炎症。由于S1P 1受体激动剂具有抑制淋巴细胞流出的能力，因此它们在多种自身免疫性疾病中具有作为治疗剂的巨大潜力。在本文中，描述了利用包含末端羧酸的乙醇胺支架发现选择性，直接作用的S1P 1激动剂的发现。强大的S1P 1激动剂，例如化合物18a和19a，其选择性比S1P 3高1000倍以上被描述。这些化合物分别在单剂1和0.3 mpk的剂量后24小时内有效减少了大鼠的血淋巴细胞计数。讨论了这两种化合物的药效特性。在两种疾病的临床前模型中进一步研究了化合物19a，它们在大鼠佐剂性关节炎模型（AA）和小鼠实验性自身免疫性脑脊髓炎模型（EAE）中均显示出良好的疗效。